Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery a randomized, double-blind, placebo-controlled trial

Peter R. Kowey, Paul Dorian, L. Brent Mitchell, Craig M. Pratt, Denis Roy, Peter J. Schwartz, Jerzy Sadowski, Dorota Sobczyk, Andrzej Bochenek, Egon Toft

Research output: Contribution to journalArticlepeer-review

Abstract

Background-Postoperative atrial arrhythmias are common and are associated with considerable morbidity. This study was designed to evaluate the efficacy and safety of vernakalant for the conversion of atrial fibrillation (AF) or atrial flutter (AFL) after cardiac surgery. Methods and Results-This was a prospective, randomized, double-blind, placebo-controlled trial of vernakalant for the conversion of AF or AFL after coronary artery bypass graft, valvular surgery, or both. Patients were randomly assigned 2:1 to receive a 10-minute infusion of 3 mg/kg vernakalant or placebo. If AF or AFL was present after a 15-minute observation period, then a second 10-minute infusion of 2 mg/kg vernakalant or placebo was given. The primary end point was the conversion of postcardiac surgery AF or AFL to sinus rhythm within 90 minutes of dosing. In patients with AF, 47 of 100 (47%) who received vernakalant converted to SR compared with 7 of 50 (14%) patients who received placebo (P

Original languageEnglish
Pages (from-to)652-659
Number of pages8
JournalCirculation: Arrhythmia and Electrophysiology
Volume2
Issue number6
DOIs
Publication statusPublished - Dec 2009

Keywords

  • Antiarrhythmic drugs
  • Atrial fibrillation
  • Cardiac surgery

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery a randomized, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this